Nancy E. Taylor

• Assisting on a PE fund acquisition of a cGMP certified manufacturer of medical devices, drug products (OTC), and cosmetics.
• Large medical device company acquisition of a drug product for a drug-alluding stent that is regulated as a device.
• Acquisition and roll-up of several imaging companies device companies including various equipment and supplies.
• Evaluation of a potential acquisition of a large device company in the EU (including manufacturing) that has primarily 510(k) medical devices in the U.S.
• Assistance in the investment in a lab company (that includes the tests that are regulated as devices)  with several laboratory tests and 510(k) tests.
• Assisted in the “roll-up” of several Class I medical device products.
• Assisted in the evaluation of an acquisition of a large medical device company that is primarily related to hospital-based devices (beds, glucose and heart-monitoring devices, and other surgical products that are primarily class I and class II products).
• Represented Centre Partners in connection with its acquisition of Guy & O’Neill, Inc., a consumer products company that focuses on private label and contract manufacturing.
• Advised major pharmaceutical, insurance, and health care providers and employers on various health care matters, including an evaluation of health care reform on their business practices and in resolving various legal and regulatory matters before Congress and Administrative agencies.
• Involved in the development of a skilled nursing facility prospective payment system and home health care reimbursement issues. Also represented therapy and ancillary companies on reimbursement issues.
• Experienced with issues relating to managed care laws, including Medicare risk and ERISA plan requirements.
• Advised clients on the FDA approval process, principally medical devices, biologics and drug applications.
• During her tenure on Capitol Hill, drafted and was instrumental in most major health care laws enacted during the past two decades, including the Safe Medical Devices Amendments of 1988, the Nutritional Labeling and Education Act of 1990, the Clinical Laboratory Improvement Act of 1988, COBRA (extension of health benefits) the Orphan Drug Amendments of 1983, the Americans with Disabilities Act (provisions relating to health care), and many other bills included in reconciliation or as freestanding health care.

• Listed, The Best Lawyers in America, 2021-2025
  • FDA Law, 2021-2022, 2024-2025
  • Administrative/ Regulatory Law 2023-2025
• Listed, The Legal 500 United States, 2013, 2015-2024
  • Healthcare - Service Providers, "Recommended Lawyer," 2023-2024
  • Healthcare - Health Insurers, "Recommended Lawyer," 2023
• Selected,  "Life Science Star," LMG Life Sciences, 2012 and 2016-2024
• Listed, Super Lawyers magazine, Washington, D.C. Super Lawyers, 2014-2019
• Team Member, BTI Power Rankings, “The 16 Strongest Firms for ‘Go-To Outside Counsel’ Insurance Work,” 2016
• Member, Winning Team, M&A Advisor Awards, "Healthcare and Life Sciences Deal of the Year (from $10mm to $500mm)" for the Chapter 11 sale of ATLS Acquisition, LLC, dba Liberty Medical Supply, Inc., 2015
• Member, Winning Team, Global M&A Network’s Turnaround Atlas Awards, "Turnaround of the Year - Small Markets" for the restructuring and sale of ATLS Acquisition, LLC (dba Liberty Medical), 2015
• Recipient, FDA Commissioner's Special Citation, Department of Health and Human Services, Public Health Service
• Team Member, a U.S. News - Best Lawyers^® "Government Relations Law Firm of the Year," 2014
• Rated, AV Preeminent^® 5.0 out of 5

°AV^®, AV Preeminent^®, Martindale-Hubbell Distinguished^SM and Martindale-Hubbell Notable^SM are certification marks used under license in accordance with the Martindale-Hubbell^® certification procedures, standards and policies.

• Member, Law360 Health Care Editorial Advisory Board, 2023
• Member, American Bar Association
• Member, The Food and Drug Law Institute
• Member, National Health Lawyers Association
• Quality Board Member, Inova Fair Oaks Hospital